Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 8,586 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 8,586 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $29.77, for a total transaction of $255,605.22. Following the transaction, the chief operating officer directly owned 13,288 shares of the company’s stock, valued at approximately $395,583.76. This trade represents a 39.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of CSTL opened at $30.40 on Thursday. The firm has a 50-day simple moving average of $23.38 and a two-hundred day simple moving average of $26.23. The stock has a market cap of $928.72 million, a PE ratio of -46.06 and a beta of 0.98. Castle Biosciences, Inc. has a 1-year low of $17.72 and a 1-year high of $44.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. As a group, analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Summit Global Investments acquired a new position in Castle Biosciences during the 2nd quarter worth $312,000. First Bank & Trust raised its position in Castle Biosciences by 12.6% in the 2nd quarter. First Bank & Trust now owns 18,591 shares of the company’s stock valued at $443,000 after purchasing an additional 2,087 shares in the last quarter. Empowered Funds LLC raised its position in Castle Biosciences by 8.4% in the 1st quarter. Empowered Funds LLC now owns 132,184 shares of the company’s stock valued at $3,245,000 after purchasing an additional 10,264 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Castle Biosciences by 46.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,438 shares of the company’s stock valued at $305,000 after buying an additional 3,951 shares during the period. Finally, Quantinno Capital Management LP boosted its stake in shares of Castle Biosciences by 387.3% in the 1st quarter. Quantinno Capital Management LP now owns 45,476 shares of the company’s stock valued at $1,116,000 after buying an additional 36,144 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Robert W. Baird set a $36.00 target price on Castle Biosciences in a research report on Friday, July 31st. KeyCorp set a $35.00 price target on shares of Castle Biosciences in a research note on Friday, May 29th. Finally, Canaccord Genuity Group reduced their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Trending Headlines about Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The revised target indicates substantial potential upside and reflects confidence in Castle Biosciences’ diagnostic-testing growth outlook. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest quarterly results exceeded expectations, with revenue of $99.86 million versus the $86.23 million analyst consensus and a loss of $0.07 per share versus expectations for a $0.41 loss. The results support the case for improving operating performance, although the company remains unprofitable.
• Neutral Sentiment: Recent coverage highlighted developments involving Castle Biosciences’ diagnostics business, but the available details do not indicate whether the update will materially affect revenue, earnings or reimbursement expectations. Castle Biosciences diagnostics update
• Negative Sentiment: Multiple insiders disclosed stock sales totaling approximately $1.68 million. Derek J. Maetzold sold 28,646 shares, COO Kristen M. Oelschlager sold 8,586 shares, and Tobin W. Juvenal sold 19,040 shares in transactions conducted from July 31 through August 3. The sales reduced their holdings and may weigh on investor sentiment, particularly after the stock’s recent strength. However, all reported transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal than discretionary sales. Castle Biosciences insider sales filing

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.